- September 28, 2016MSD K.K. receives manufacturing and marketing approval for DESALEX Tablets 5mg for treatment of allergic diseases
- September 15, 2016MSD and Kyorin Sign Agreement on Co-Promotion of Therapeutic Agent for Allergic Rhinitis, NASONEX Nasal
- September 1, 2016Release of Montelukast tablets 10mg「KM」, Montelukast tablets 5mg「KM」
- July 11, 2016Kyorin Pharmaceutical and Kaken Pharmaceutical signed a Contract for the co-promotion of the anti-allergic therapeutic agent "desloratadine"
- June 1, 2016Release of Eklira 400μg Genuair 60 inhalations, a treatment for COPD
- May 25, 2016MSD's investigational antiallergic agent desloratadine to be exclusively marketed by Kyorin
- March 30, 2016Kyorin and Kissei signed an Agreement for Co-Development and Co-Marketing of KRP-114V
- February 23, 2016Announcement Regarding Montelukast tablets 10mg「KM」, Montelukast tablets 5mg「KM」